Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EBIT (2016 - 2025)

Historic EBIT for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$21.1 million.

  • Cartesian Therapeutics' EBIT fell 1986.34% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.5 million, marking a year-over-year decrease of 7102.88%. This contributed to the annual value of -$43.9 million for FY2024, which is 4920.27% up from last year.
  • Per Cartesian Therapeutics' latest filing, its EBIT stood at -$21.1 million for Q3 2025, which was down 1986.34% from -$21.8 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' EBIT registered a high of $13.9 million during Q2 2022, and its lowest value of -$36.3 million during Q4 2023.
  • In the last 5 years, Cartesian Therapeutics' EBIT had a median value of -$13.1 million in 2023 and averaged -$9.7 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' EBIT surged by 296637.17% in 2022, and later tumbled by 71707.32% in 2023.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' EBIT stood at $4.1 million in 2021, then plummeted by 308.34% to -$8.5 million in 2022, then tumbled by 327.64% to -$36.3 million in 2023, then grew by 26.43% to -$26.7 million in 2024, then grew by 21.19% to -$21.1 million in 2025.
  • Its EBIT was -$21.1 million in Q3 2025, compared to -$21.8 million in Q2 2025 and -$21.9 million in Q1 2025.